Evidence map›Paper›PMID 35474000›Full record

ArticleRegulatory toxicology and pharmacology : RTP2022

Corrigendum to a cross-industry collaboration to assess if acute toxicity (Q)SAR models are fit-for-purpose for GHS classification and labelling. Regulatory toxicology and pharmacology (2021) 104843.

Joel Bercu, Melisa J Masuda Herrera, Alejandra Trejo-Martin, Catrin Hasselgren, Jean Lord, Jessica Graham, Matthew Schmitz, Lawrence Milchak, Colin Owens, Surya Hari Lal and 12 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Regulatory toxicology and pharmacology : RTP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Joel BercuGilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.
Melisa J Masuda HerreraGilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.
Alejandra Trejo-MartinGilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.
Catrin HasselgrenGenentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Jean LordUltragenyx, 60 Leveroni Court, Novato, CA, 94949, USA.
Jessica GrahamBristol Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.
Matthew SchmitzAbbVie Inc., North Chicago, IL, USA.
Lawrence Milchak3M Company, 3M Center, St. Paul, MN, 55144-1000, USA.
Colin Owens3M Company, 3M Center, St. Paul, MN, 55144-1000, USA.
Surya Hari LalSyngenta Crop Protection, Product Safety Department, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK.
Richard Marchese RobinsonSyngenta Crop Protection, Product Safety Department, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK.
Sarah WhalleySyngenta Crop Protection, Product Safety Department, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK.
Phillip BellionDSM Nutritional Products, Kaiseraugst, Switzerland.
Anna VuorinenDSM Nutritional Products, Kaiseraugst, Switzerland.
Kamila GromekGalapagos SASU, 102 Avenue Gaston Roussel, 93230, Romainville, France.
William A HawkinsGlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom.
Iris Van de GevelJanssen Pharmaceutical Companies of Johnson & Johnson, 2340, Beerse, Belgium.
Kathleen VriensJanssen Pharmaceutical Companies of Johnson & Johnson, 2340, Beerse, Belgium.
Raymond KemperVertex Pharmaceuticals Inc., Discovery and Investigative Toxicology, 50 Northern Ave, Boston, MA, USA.
Russell NavenVertex Pharmaceuticals Inc., Discovery and Investigative Toxicology, 50 Northern Ave, Boston, MA, USA.
Pierre FerrerDepartment of Veterinary Physiology and Pharmacology, Interdisciplinary Faculty of Toxicology Program, Texas A&M University, 4466 TAMU, College Station, TX, 77843-4466, USA.
Glenn J MyattLeadscope (an Instem Company), 1393 Dublin Rd, Columbus, OH, 43215, USA. Electronic address: glenn.myatt@instem.com.

Funding

Rapid response toxicology prediction platformR44ES026909 · NIEHS · LEADSCOPE, INC. · PI MYATT, GLENN JOHN · 2018 to 2019
$1000k
NIEHS NIH HHS R44 ES026909
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35474000
PMCPMC9200224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.